Drug intelligence / Profile preview

ModCAR-CD20

Development stage: Preclinical
Lead developer: Hauul Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ModCAR-CD20 is a preclinical-stage modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio. The therapy is designed to target CD20, a B-lymphocyte antigen frequently expressed in various hematologic malignancies. The 'ModCAR' platform utilizes a modular architecture intended to provide enhanced control, safety, or multi-targeting capabilities compared to traditional CAR-T cell therapies. The program is currently in preclinical development for the treatment of several blood cancers, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL), as well as myeloid malignancies like acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

Other names: ModCAR-CD20ModCAR-CD-20ModCAR-CD 20

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on ModCAR-CD20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ModCAR-CD20.

Explore the full profile